- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02476539
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer
The purposes of this study are to assess the safety, tolerability and pharmacokinetics of Hemay022. The secondary purpose of this study is to assess the efficacy of Hemay022 in the treatment of HER2-positive advanced breast cancer.
The study will be conducted in two parts. Part one, trial will be conducted in 18-30 subjects to determine safety and tolerability of Hemay022 in patients with HER2-positive advanced breast cancer. Part two, approximately 27 additional subjects with HER2-positive advanced breast cancer, are included to better define the tolerability and preliminary efficacy of Hemay022.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Xiaoning Yang, manager
- Phone Number: 86-22-8789-9502
- Email: yangxiaoning@hemay.com.cn
Study Contact Backup
- Name: Ying Gao, manager
- Phone Number: 86-22-8789-9502
- Email: gaoying@hemay.com.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female subjects aged 18 to 65 years;
- Histologically or cytologically confirmed and radiologically diagnosed advanced breast cancer subjects; and subjects who have failed standard therapy,or no effective therapy available for such subjects
- HER2 over-expression by IHC with score of 3+, or 2+ with FISH confirmation;
- Preferably measurable tumour lesion as defined by RECIST criteria1.1;
- Subjects have received chemotherapy at least 4 weeks prior to screening (at least 6 weeks of washout time frame if treated with mitomycin and nitrosoureas) and must have recovered from any toxic effects of the treatment --- to CTCAE 4.03≤ Grade 1;
- ECOG Performance Status of 0,1;
- Life expectancy of at least three months;
Adequate bone marrow, liver, kidney function, meeting the following creteria:
ANC≥1.5×109/L, HB≥90g/L, PLT≥75×109/L; TBIL≤1.5×ULN, ALT≤1.5×ULN, AST≤1.5×ULN; Cr ≤1×ULN; BUN ≤1×ULN;
- Left ventricular ejection fraction (LVEF) ≧50% as measured by Ultrasonic cardiogram (UCG)
- All female and male subjects must agree and commit to the use of a reliable contraceptive regimen for the duration of the study and for at least 12 weeks after at the last dose of test article. Female subjects must have a negative serum or urine pregnancy test performed within 7 days prior to treatment;
- Ability to understand and the be willingness to sign a written informed consent before study entry;
- subjects would have good communication with the investigator and could comply with protocol
Exclusion Criteria:
- Patients with parenteral nutrition; malabsorption syndrome; or any condition possibly affecting drug absorption or inability to tolerate oral medications;
- Clinically QTc prolongation, ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 1 year, congestive heart failure, symptoms requiring medicine treatment patients with coronary heart disease;
- Ventricular ejection fraction (LVEF) <50%;
- Active infection (ie, requiring intravenous antibiotic or antiviral agent);
- Active central nervous system metastases
- Have received other clinical trials treatment within the 4 weeks prior to study;
- Have received other target therapy within the 4 weeks prior to study;
- Pregnant or breast feeding women;
- Have a known hypersensitivity to the test article or any of the excipient of the test article;
- Evidence of significant medical illness or abnormal laboratory finding that would make the subject inappropriate for this study by the investigator's judgment.
- Subjects cannot complete the study due to other reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hemay022
Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days. Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: 4 weeks of treatment
|
4 weeks of treatment
|
Observed maximum concentration of Hemay022
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
Time of maximum concentration of Hemay022
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
Area under the plasma concentration versus time curve of Hemay022
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
Trough Plasma Concentrations of Hemay022
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose on day 1 and day 35
|
Predose plasma concentration
Time Frame: Predose on day 7, 14, 21
|
Predose on day 7, 14, 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease control rate (complete response rate + partial response rate + stable disease rate) according to RECIST v1.1
Time Frame: 4 weeks of treatment
|
4 weeks of treatment
|
Objective response rate (complete response rate + partial response rate) according to RECIST v1.1
Time Frame: 4 weeks of treatment
|
4 weeks of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hemay022-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2 Positive Breast Cancer
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
Clinical Trials on Hemay022
-
Tianjin Hemay Oncology Pharmaceutical Co., LtdUnknown
-
Tianjin Hemay Pharmaceutical Co., LtdCompleted
-
Tianjin Hemay Oncology Pharmaceutical Co., LtdRecruiting
-
Tianjin Hemay Pharmaceutical Co., LtdRecruiting